IASO Biotherapeutics' Equecabtagene Autoleucel Receives the NMPA’s IND Approval for Neuromyelitis Optica Spectrum Disorder
Shots:
- The application was based on an investigator-initiated study to evaluate equecabtagene autoleucel for NMOSD
- As of the cut-off date of Mar 2022, 12 patients received equecabtagene autoleucel cell reinfusion incl. 3 in 0.5×106 & 9 in 1.0×106 CAR-T cells/kg dose group & was safe in both dose groups, all patients experienced grade 1-2 CRS with no ICANS events, improvement in EDSS scores after infusion, 50% experienced improved visual acuity, ability to walk (67%), and bladder function (75%), 92% did not observe any disease recurrence after a median follow-up of 5.5mos.
- The therapy can reduce the disability score & improve the functions of sensory, nervous & motor systems. The therapy has received BTD from the NMPA while ODD from the US FDA
Ref: PRNewswire | Image: IASO Biotherapeutics
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
